Actaea Spicata Root Antimony Trisulfide Arnica Mon

證據等級: L5 預測適應症: 0

目錄

  1. Actaea Spicata Root Antimony Trisulfide Arnica Mon
  2. Multi-Ingredient Homeopathic Formula: Repurposing Evaluation Not Feasible
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. US Market Information
    7. Safety Considerations
    8. Conclusion and Next Steps
    9. Disclaimer

## 藥師評估報告

Multi-Ingredient Homeopathic Formula: Repurposing Evaluation Not Feasible

One-Sentence Summary

This submission contains a 16-ingredient multi-component formula that appears to be a homeopathic preparation, including botanicals, mineral salts, and biologically derived substances. The TxGNN model returned no predicted indications for this entry, and no original approved indication, clinical trial evidence, or safety data is available. With zero predicted indications and no regulatory footprint, a meaningful drug repurposing evaluation cannot be completed at this time.


Quick Overview

Item Content
Original Indication Not available (no approved indications on record)
Predicted New Indication None (TxGNN returned no predictions)
TxGNN Prediction Score N/A
Evidence Level L5 — Model prediction only; in this case no predictions were generated
US Market Status Not marketed
Number of NDAs 0
Recommended Decision Hold

Why is This Prediction Reasonable?

No TxGNN prediction was generated for this compound, so a mechanistic rationale for a new indication cannot be constructed.

The ingredient list comprises 16 substances spanning botanical extracts (Arnica montana, Chelidonium majus, Veratrum album root, Ledum palustre, Ocimum americanum), mineral compounds (Zinc oxide, Silver nitrate, Antimony trisulfide, Mercuric cyanide, Mercurius solubilis), a petroleum-derived substance (Kerosene), a marine-derived secretion (Hexaplex trunculus hypobranchial gland juice), and additional herbs (Actaea spicata, Clematis recta, Cypripedium parviflorum var. pubescens, Pseudognaphalium obtusifolium). This combination is characteristic of a homeopathic combination product, where ingredients are used in ultra-diluted form and do not necessarily exhibit conventional pharmacological activity at detectable concentrations.

Because no DrugBank ID could be resolved for this multi-ingredient entry and no mechanistic data is available, it is not possible to assess whether any shared mechanism might connect the formula to a new therapeutic indication.


Clinical Trial Evidence

Currently no related clinical trials registered.


Literature Evidence

Currently no related literature available.


US Market Information

This formula has no US market authorizations on record. No NDA or equivalent regulatory filing was identified.


Safety Considerations

Several ingredients in this formula warrant attention even in the absence of formal safety data:

  • Potentially toxic ingredients: Mercuric cyanide, Mercurius solubilis (mercury-based), and Antimony trisulfide are classified as toxic substances in conventional pharmacology. Kerosene is a petroleum derivative with known toxicity on ingestion.
  • Regulatory gap: No package insert, label warnings, or contraindication data are available for this formulation. Homeopathic preparations are not subject to the same evidence requirements as conventional drugs in most jurisdictions.
  • Drug interaction data: No DDI records were found.

Please refer to the product’s original package insert (if available) for safety information. Given the presence of mercury and antimony compounds, independent toxicological review is strongly recommended before any clinical use.


Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN predictions were generated, no approved indication exists, and the formula contains several substances (mercury compounds, antimony trisulfide, kerosene) that raise serious safety concerns requiring toxicological clarification before any repurposing pathway can be considered.

To proceed, the following is needed:

  • Confirm whether this is intended as a homeopathic product and, if so, identify the registered homeopathic indication and dilution levels for each ingredient
  • Resolve a single primary active ingredient or a well-characterized combination that can be mapped to a DrugBank entry, enabling TxGNN prediction
  • Obtain or commission a toxicological assessment covering mercury- and antimony-containing ingredients, including evaluation of cumulative heavy metal exposure
  • Identify any existing national or regional regulatory filings (homeopathic monographs, traditional medicine registrations) that document the formula’s intended use
  • Once a DrugBank ID is assigned, re-run the evidence collection pipeline to obtain clinical trial and literature evidence for any predicted indication

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Copyright © 2026 UsTxGNN Project. For research purposes only.

This site uses Just the Docs, a documentation theme for Jekyll.